This Urban Outfitters Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: ELAN Buy/$32, IRTC Overweight/$160, BAND Equal-Weight/$56, HRTG Market Perform, and URBN Buy/$100.
Stocks · News reference
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Initiates Coverage On Bandwidth with Equal-Weight Rating, Announces Price Target of $56
Morgan Stanley analyst Elizabeth Porter initiates coverage on Bandwidth (NASDAQ:BAND) with a Equal-Weight rating and announces Price Target of $56.
Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6
Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia
The trial has received Human Research Ethics Committee (HREC) approval and completed the Clinical Trial Notification (CTN) process with Australia’s Therapeutic Goods Administration (TGA) and has also been submitted for
8-K filing — Editas Medicine, Inc. (EDIT)
Filed: 2026-10-08 AccNo: 0001650664-26-000093 Size: 292 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Lakefront kondigt de verkoop aan van haar preklinische CAR-T-programma’s aan Armed Cell Therapeutics
Lakefront Biotherapeutics has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV for an €8 million upfront payment plus up to $230 million in milestone payments and royalties. The transaction marks the near-completion of Lakefront's previously announced wind-down of cell therapy activities, allowing the company to focus on its T-cell engager pipeline while providing shareholders potential upside from Armed Cell's future progress.